Prophylactic implantable cardioverter defibrillator therapy did not reduce mortality in patients with a prior myocardial infarction, persistent moderate left ventricular systolic dysfunction and ...

Prophylactic, substrate-guided ablation of LV scars reduced the risk for subsequent VT in patients with ICDs for post-MI arrhythmias. Implantable cardioverter-defibrillator (ICD) therapy reduces ...

KIRKLAND, Wash.--(BUSINESS WIRE)--Kestra ™ Medical Technologies, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) Premarket Approval for the ASSURE ® Wearable ...

An extravascular ICD with a substernal lead might retain the benefits, and avoid the risks, of transvenous and subcutaneous ICDs, but data on safety and efficacy are needed. New research findings are ...

More than three decades have transpired since the inception of transtelephonic pacemaker monitoring. 1 3 This modality was identified as a useful method for tracking the function of pacemaker systems, ...

AtaCor Medical announced today that it entered a financing worth up to $75 million to support its U.S. FDA pivotal study.

Element Science acquired a CE mark in Europe and a green light in the U.K. for its patch-based cardioverter defibrillator, designed to provide an easier-to-wear device for people in danger of sudden ...

Additional Health Plans Contract with Kestra Medical Technology Services, Inc., increasing patient access to the ASSURE system as a covered service. KIRKLAND, Wash.--(BUSINESS WIRE)--Kestra Medical ...

Please provide your email address to receive an email when new articles are posted on . Reducing the current 6-month driving restriction following a new implantable cardioverter defibrillator to 3 ...

Background Cardiac surgery carries a heightened risk of bradyarrhythmias, but current permanent pacemaker (PPM) implantation ...